GW501516 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA as a metabolic modulator. |
| Approved medical use | None in major jurisdictions | Not a registered drug. |
| Common test matrix | Urine | Most anti-doping samples use urine. |
| Typical detection method | LC-MS/MS | Detects parent compound and metabolites. |
| Reference standard storage | -20 °C, desiccated | Typical for analytical standards. |
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
=== Symptoms and treatment === The diagnosis of pufferfish poisoning is based on the observed symptomatology and recent dietary history. Symptoms typically develop within 30 minutes of ingestion, but may be delayed by up to four hours; however, if the dose is fatal, symptoms are usually present within 17 minutes of ingestion. Having pins and needles of the lips and tongue is followed by developing it in the extremities, hypersalivation, sweating, headache, weakness, lethargy, incoordination, tremor, paralysis, bluish skin, loss of voice, difficulty swallowing, and seizures. The gastrointestinal symptoms are often severe and include nausea, vomiting, diarrhoea, and abdominal pain; death is usually secondary to respiratory failure. There is increasing respiratory distress, speech is affected, and the victim usually exhibits shortness of breath, excess pupil dilation, and abnormally low blood pressure. Paralysis increases, and convulsions, mental impairment, and irregular heartbeats may occur. The victim, although completely paralysed, may be conscious and in some cases completely lucid until shortly before death, which generally occurs within 4 to 6 hours (range ~20 minutes to ~8 hours). However, some victims enter a coma.
== Functions == After water, proteins account for more mass in an organism than any other type of molecule. Protein is present in every cell, and it is a structural component of every body tissue and organ, including hair, skin, blood, and bone. Protein is especially abundant in muscle. Cellular messengers (hormones) and transport molecules are constructed from proteins, including enzymes and antibodies, as are cell membrane components, such as glycoproteins, G proteins, and ion channels. The types of amino acids and their sequence determine the unique 3-dimensional structure and function of a protein. Amino acids obtained through protein catabolism also enable the biosynthesis of non-protein molecules that are essential for life, such as nucleotides, certain neurotransmitters, and heme.
The 1st Infantry Division's 5th Battalion, 16th Infantry also played a significant role clearing the trenches and captured 160 Iraqi soldiers in the process. Once into Iraqi territory Task Force 1–41 Infantry encountered multiple Iraqi defensive positions and bunkers. These defensive positions were occupied by a brigade-sized element. Task Force 1–41 Infantry elements dismounted and prepared to engage the enemy soldiers who occupied these well-prepared and heavily fortified bunkers. The Task Force found itself engaged in six hours of combat in order to clear the extensive bunker complex. The Iraqis engaged the Task Force with small arms fire, RPGs, mortar fire, and what was left of Iraqi artillery assets. A series of battles unfolded resulting in heavy Iraqi casualties and the Iraqis being removed from their defensive positions with many becoming prisoners of war. Some escaped to be killed or captured by other coalition forces. In the process of clearing the bunkers, Task Force 1–41 captured two brigade command posts and the command post of the Iraqi 26th Infantry Division. The Task Force also captured a brigade commander, several battalion commanders, company commanders, and staff officers. As combat operations progressed Task Force 1–41 Infantry engaged at short range multiple dug in enemy tanks in ambush positions. For a few hours, bypassed Iraqi RPG-equipped anti-tank teams, T-55 tanks, and dismounted Iraqi infantry fired at passing American vehicles, only to be destroyed by other US tanks and fighting vehicles following the initial forces.
Big dynorphin acts as a potent full agonist at the human κ-opioid receptor (KOR), exhibiting extremely high relative efficacy at this target. In one binding assay it demonstrated similar affinity to dynorphin A, but about 14 to 32-fold higher potency to activate G proteins than other dynorphin peptides. In contrast, other studies have suggested similar or higher potencies of other dynorphins. The peptide is also an agonist of other opioid receptors, It is 70-fold selective towards KOR over μ-opioid receptors (MOR) and 200 over δ-opioid receptor (DOR). In older guinea-pig ileum bioassay measuring native receptor function, big dynorphin shows approximately 10-20-fold reduced potency relative to dynorphin A, possibly due to conformational constraints of the larger peptide affecting receptor binding in peripheral tissue. This discrepancy suggests that big dynorphin's efficacy in human KOR systems may not translate directly to potency in peripheral tissue. Big dynorphin could theoretically produce some of the classical pharmacological effects associated with KOR agonism such as dysphoria, dissociation, and sedation, but this has not been directly evaluated. Similarly biased signaling of big dynorphin at KOR has not yet been assessed.
== Further reading == Abbott G. European and Muscovite: Ivan Kireevsky and the origins of Slavophilism (Cambridge University Press, 1972) Agnew H. Origins of the Czech National Renascence (University of Pittsburgh Press, 1993) Carole R. The Slovenes and Yugoslavism, 1890-1914 (Columbia University Press, 1977) Djokic D. (ed.) Yugoslavism. Histories of a Failed Idea, 1918-1992 (Hurst and Company, 2003) Gasor A., Karl L., Troebst S. (eds.) Post-Panslavismus. Slavizität, Slavische Idee und Antislavismus im 20. und 21. Jahrhundert (Wallstein Verlag, 2014) Geier, Wolfgang (2022). Panslawismus [Pan-Slavism]. Enzyklopädie des europäischen Ostens, vol. 20,4. Klagenfurt: Wieser, ISBN 978-3-99029-535-9. Golub I., Bracewell C. The Slavic Idea of Juraj Krizanic, Harvard Ukrainian Studies 3-4 (1986). Grigorieva, Anna A. (2010). "Pan-Slavism in Central and Southeastern Europe" (PDF). Journal of Siberian Federal University. Humanities & Social Sciences. 3 (1): 13–21. Retrieved 22 September 2018. Kohn, Hans. Nationalism: Its meaning and history (van Nostrand, 1955). Kohn, Hans (1961). "The Impact of Pan-Slavism on Central Europe". The Review of Politics. 23 (3): 323–333. doi:10.1017/s0034670500008767. JSTOR 1405438. S2CID 145066436. Kostya S. Pan-Slavism (Danubian Press, 1981) Osmańczyk, Edmund Jan (2003). "Pan-Slavism". Encyclopedia of the United Nations and International Agreements: N to S. Taylor & Francis. pp. 1762–. ISBN 9780415939232. Retrieved 22 September 2018. Petrovich B.M.
Sources: en.wikipedia.org
=== London Hospital === Florey was unhappy working at London Hospital; he disliked the long daily commute from Chobham that put his experimental work at the mercy of the railway timetable. In the summer Howard and Ethel lived in a flat in Belsize Park so he could devote more time to his work. He wrote up the results of the research he had done in New York on lacteals and lymphatic capillaries, which was published in the Journal of Physiology in 1927. Florey then embarked on writing a thesis for a fellowship at Gonville and Caius College, Cambridge, where he became an unofficial fellow in 1926. His thesis on "Physiology and pathology of the circulation of the blood and lymph" was accepted, and his fellowship awarded in 1927. He also continued his work on the secretion of mucus. London Hospital's facilities for the laboratory animals he needed for his research were unsatisfactory, so these experiments were carried out at Oxford and Cambridge. However, he was able to study the lacteals in patients undergoing abdominal surgery.
The only drug currently approved for stroke treatment is tPA, which can cause dangerous brain bleeding. In 2005, Griffin et al proposed using Activated Protein C in conjunction with tPA to protect the brain from tPA’s harmful side-effects. APC activates protease-activated receptor 1 (PAR-1), which plays a role in the interaction of coagulation and inflammation. The 3K3A-APC was designed to have more activity at protease-activated receptor 1 (PAR-1) and less anticoagulative effect than activated protein C. The phase 2 trial, RHAPSODY, was performed in the lab of Berislav Zlokovic, the scientific founder of ZZ Biotech, to determine safety and tolerability of the drug. A phase 3 $30 million trial, RHAPSODY-2, was planned to determine safety and efficacy for treatment of ischemic stroke. However, on November 16, 2023, the National Institutes of Health (NIH) paused the start of the human trial of 3K3A-APC after an investigation by Science Magazine.
An important use of 237Np is as a precursor in plutonium-238 production, where it is irradiated with neutrons to form 238Pu, an alpha emitter for radioisotope thermal generators for spacecraft and military applications. 237Np will capture a neutron to form 238Np and beta decay with a half-life of just over two days to 238Pu.
Three basic battery types are used in 2020s-era electric vehicles: cylindrical cells (e.g., Tesla), prismatic pouch (e.g., from LG), and prismatic can cells (e.g., from LG, Samsung, Panasonic, and others). Lithium-ion flow batteries have been demonstrated that suspend the cathode or anode material in an aqueous or organic solution. As of 2014, the smallest Li-ion cell was pin-shaped with a diameter of 3.5 mm and a weight of 0.6 g, made by Panasonic. A coin cell form factor is available for LiCoO2 cells, usually designated with a "LiR" prefix.
Sources: en.wikipedia.org
Legal status varies by country, but cardarine is not approved as a medicine in major jurisdictions. It is often sold as a research chemical, a category that may not be lawful for human use. Buyers should check local laws and product labels carefully.
Anti-doping laboratories use LC-MS/MS to detect GW501516 and its metabolites, usually in urine. The method can identify the parent compound at low concentrations. Detection windows vary with dose and individual factors.
No, cardarine has no approved medical uses in major jurisdictions. Early research explored metabolic conditions, but those programs were discontinued. It is not a registered treatment for any disease.
It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.